Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment
The study was a 1 year randomized, double-blind, placebo-controlled study of ibandronate treatment in postmenopausal, osteopenic women. Participants were followed for 1 year after withdrawal of treatment. All women were at least 10 years past menopause and had a baseline bone mineral density (BMD) a...
Gespeichert in:
| Veröffentlicht in: | Bone (New York, N.Y.) N.Y.), 1998-05, Vol.22 (5), p.559-564 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 564 |
|---|---|
| container_issue | 5 |
| container_start_page | 559 |
| container_title | Bone (New York, N.Y.) |
| container_volume | 22 |
| creator | Ravn, P Christensen, J.O Baumann, M Clemmesen, B |
| description | The study was a 1 year randomized, double-blind, placebo-controlled study of ibandronate treatment in postmenopausal, osteopenic women. Participants were followed for 1 year after withdrawal of treatment. All women were at least 10 years past menopause and had a baseline bone mineral density (BMD) at the distal forearm at least 1.5 standard deviations below the premenopausal mean peak value. A total of 141 women (78%) completed the first year, and 119 women (66%) the second year of the study. The dose-response data of the first year have been published previously (Ravn et al. Bone 19:527–533;1996). In this study, we analyzed the biochemical markers as predictors of response in bone mass during ibandronate treatment, and report withdrawal data from the last year of the study, when ibandronate was discontinued. The relative change in the biochemical markers was significantly correlated to the response in BMD. At 12 months, the
r values ranged from −0.29 to −0.47 (
p < 0.01) and were highest for CrossLaps (uCL) and osteocalcin (OC
N-MID). The quartiles of women with the most reduced concentrations of uCL and OC
N-MID during treatment showed a 360–430% higher response in BMD compared to quartiles with less reduced concentrations (
p < 0.01). During the withdrawal period, uCL and alkaline phosphatase (AP) returned to baseline values 12 months after discontinuation of treatment in all groups, whereas OC
N-MID and bone-specific AP were still reduced 10%–25% in the groups previously treated with the highest doses of ibandronate (1.0–5.0 mg) (
p < 0.01). In the withdrawal period, BMD decreased equally in all groups (analysis of variance; not significant); with a linear rate of 2%/year on average (
p < 0.05 to < 0.001) at the spine and femur. In conclusion, uCL and OC
N-MID can be used to predict the response in bone mass during ibandronate treatment. The bone loss that resumes after withdrawal of ibandronate treatment is of a magnitude similar to that of normal postmenopausal bone loss. |
| doi_str_mv | 10.1016/S8756-3282(98)00044-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79896514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S8756328298000441</els_id><sourcerecordid>79896514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-6f1efb8e22aff9e339340dac2478a536f22835384ab412e162c9d65e3c7cf7e63</originalsourceid><addsrcrecordid>eNqFkc1uUzEQhS0EKqHwCJW8QAgWt_jnXv-wQW2AUqkIJIpYWo7vuDHk2sV2QLwBj12nSdMlq5FmvjMzOgehI0qOKaHi9VclB9FxpthLrV4RQvq-ow_QjCrJOyYFf4hme-QxelLKjwZxLekBOtCCEKnZDP2bL228goJDxKchuSVMwdkV_mTzT8gF2zji0xShNUrBJ75Cxt9DXY7Z_mlY8vh80Zicoq2ALzPYOkGsb_CXDGNwNaS4ge5X3N17t84hXt0rnqJH3q4KPNvVQ_Ttw_vL-cfu4vPZ-fzkonP9MNROeAp-oYAx670GzjXvyWgd66WyAxeeMcUHrnq76CkDKpjToxiAO-m8BMEP0Yvt3uucfq2hVDOF4mC1shHSuhiplRYD7Rs4bEGXUykZvLnOYbL5r6HEbBIwtwmYjb1GK3ObgKFNd7Q7sF5MMO5VO8vb_Plubktz2mcbXSh7jDFGFNMNe7vFoJnxO0A2xQWIrrmawVUzpvCfR24AhsmjRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79896514</pqid></control><display><type>article</type><title>Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Ravn, P ; Christensen, J.O ; Baumann, M ; Clemmesen, B</creator><creatorcontrib>Ravn, P ; Christensen, J.O ; Baumann, M ; Clemmesen, B</creatorcontrib><description>The study was a 1 year randomized, double-blind, placebo-controlled study of ibandronate treatment in postmenopausal, osteopenic women. Participants were followed for 1 year after withdrawal of treatment. All women were at least 10 years past menopause and had a baseline bone mineral density (BMD) at the distal forearm at least 1.5 standard deviations below the premenopausal mean peak value. A total of 141 women (78%) completed the first year, and 119 women (66%) the second year of the study. The dose-response data of the first year have been published previously (Ravn et al. Bone 19:527–533;1996). In this study, we analyzed the biochemical markers as predictors of response in bone mass during ibandronate treatment, and report withdrawal data from the last year of the study, when ibandronate was discontinued. The relative change in the biochemical markers was significantly correlated to the response in BMD. At 12 months, the
r values ranged from −0.29 to −0.47 (
p < 0.01) and were highest for CrossLaps (uCL) and osteocalcin (OC
N-MID). The quartiles of women with the most reduced concentrations of uCL and OC
N-MID during treatment showed a 360–430% higher response in BMD compared to quartiles with less reduced concentrations (
p < 0.01). During the withdrawal period, uCL and alkaline phosphatase (AP) returned to baseline values 12 months after discontinuation of treatment in all groups, whereas OC
N-MID and bone-specific AP were still reduced 10%–25% in the groups previously treated with the highest doses of ibandronate (1.0–5.0 mg) (
p < 0.01). In the withdrawal period, BMD decreased equally in all groups (analysis of variance; not significant); with a linear rate of 2%/year on average (
p < 0.05 to < 0.001) at the spine and femur. In conclusion, uCL and OC
N-MID can be used to predict the response in bone mass during ibandronate treatment. The bone loss that resumes after withdrawal of ibandronate treatment is of a magnitude similar to that of normal postmenopausal bone loss.</description><identifier>ISSN: 8756-3282</identifier><identifier>EISSN: 1873-2763</identifier><identifier>DOI: 10.1016/S8756-3282(98)00044-1</identifier><identifier>PMID: 9600792</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Alkaline Phosphatase - blood ; Biological and medical sciences ; Biomarkers - blood ; Biomarkers - urine ; Bisophosphonate ; Bone Density - drug effects ; Bone Density - physiology ; Bone Diseases, Metabolic - blood ; Bone Diseases, Metabolic - drug therapy ; Bone Diseases, Metabolic - urine ; Bone Resorption - drug therapy ; Bone turnover ; Bones, joints and connective tissue. Antiinflammatory agents ; Collagen - blood ; Collagen Type I ; Diphosphonates - administration & dosage ; Diphosphonates - therapeutic use ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Femur - drug effects ; Femur - physiology ; Follow-Up Studies ; Forearm ; Humans ; Ibandronate ; Ibandronic Acid ; Medical sciences ; Middle Aged ; Osteocalcin - blood ; Peptides - blood ; Pharmacology. Drug treatments ; Postmenopausal osteoporosis ; Prediction ; Spine - drug effects ; Spine - physiology ; Withdrawal</subject><ispartof>Bone (New York, N.Y.), 1998-05, Vol.22 (5), p.559-564</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-6f1efb8e22aff9e339340dac2478a536f22835384ab412e162c9d65e3c7cf7e63</citedby><cites>FETCH-LOGICAL-c455t-6f1efb8e22aff9e339340dac2478a536f22835384ab412e162c9d65e3c7cf7e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S8756328298000441$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2220829$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9600792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ravn, P</creatorcontrib><creatorcontrib>Christensen, J.O</creatorcontrib><creatorcontrib>Baumann, M</creatorcontrib><creatorcontrib>Clemmesen, B</creatorcontrib><title>Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment</title><title>Bone (New York, N.Y.)</title><addtitle>Bone</addtitle><description>The study was a 1 year randomized, double-blind, placebo-controlled study of ibandronate treatment in postmenopausal, osteopenic women. Participants were followed for 1 year after withdrawal of treatment. All women were at least 10 years past menopause and had a baseline bone mineral density (BMD) at the distal forearm at least 1.5 standard deviations below the premenopausal mean peak value. A total of 141 women (78%) completed the first year, and 119 women (66%) the second year of the study. The dose-response data of the first year have been published previously (Ravn et al. Bone 19:527–533;1996). In this study, we analyzed the biochemical markers as predictors of response in bone mass during ibandronate treatment, and report withdrawal data from the last year of the study, when ibandronate was discontinued. The relative change in the biochemical markers was significantly correlated to the response in BMD. At 12 months, the
r values ranged from −0.29 to −0.47 (
p < 0.01) and were highest for CrossLaps (uCL) and osteocalcin (OC
N-MID). The quartiles of women with the most reduced concentrations of uCL and OC
N-MID during treatment showed a 360–430% higher response in BMD compared to quartiles with less reduced concentrations (
p < 0.01). During the withdrawal period, uCL and alkaline phosphatase (AP) returned to baseline values 12 months after discontinuation of treatment in all groups, whereas OC
N-MID and bone-specific AP were still reduced 10%–25% in the groups previously treated with the highest doses of ibandronate (1.0–5.0 mg) (
p < 0.01). In the withdrawal period, BMD decreased equally in all groups (analysis of variance; not significant); with a linear rate of 2%/year on average (
p < 0.05 to < 0.001) at the spine and femur. In conclusion, uCL and OC
N-MID can be used to predict the response in bone mass during ibandronate treatment. The bone loss that resumes after withdrawal of ibandronate treatment is of a magnitude similar to that of normal postmenopausal bone loss.</description><subject>Aged</subject><subject>Alkaline Phosphatase - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - urine</subject><subject>Bisophosphonate</subject><subject>Bone Density - drug effects</subject><subject>Bone Density - physiology</subject><subject>Bone Diseases, Metabolic - blood</subject><subject>Bone Diseases, Metabolic - drug therapy</subject><subject>Bone Diseases, Metabolic - urine</subject><subject>Bone Resorption - drug therapy</subject><subject>Bone turnover</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Collagen - blood</subject><subject>Collagen Type I</subject><subject>Diphosphonates - administration & dosage</subject><subject>Diphosphonates - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Femur - drug effects</subject><subject>Femur - physiology</subject><subject>Follow-Up Studies</subject><subject>Forearm</subject><subject>Humans</subject><subject>Ibandronate</subject><subject>Ibandronic Acid</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteocalcin - blood</subject><subject>Peptides - blood</subject><subject>Pharmacology. Drug treatments</subject><subject>Postmenopausal osteoporosis</subject><subject>Prediction</subject><subject>Spine - drug effects</subject><subject>Spine - physiology</subject><subject>Withdrawal</subject><issn>8756-3282</issn><issn>1873-2763</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uUzEQhS0EKqHwCJW8QAgWt_jnXv-wQW2AUqkIJIpYWo7vuDHk2sV2QLwBj12nSdMlq5FmvjMzOgehI0qOKaHi9VclB9FxpthLrV4RQvq-ow_QjCrJOyYFf4hme-QxelLKjwZxLekBOtCCEKnZDP2bL228goJDxKchuSVMwdkV_mTzT8gF2zji0xShNUrBJ75Cxt9DXY7Z_mlY8vh80Zicoq2ALzPYOkGsb_CXDGNwNaS4ge5X3N17t84hXt0rnqJH3q4KPNvVQ_Ttw_vL-cfu4vPZ-fzkonP9MNROeAp-oYAx670GzjXvyWgd66WyAxeeMcUHrnq76CkDKpjToxiAO-m8BMEP0Yvt3uucfq2hVDOF4mC1shHSuhiplRYD7Rs4bEGXUykZvLnOYbL5r6HEbBIwtwmYjb1GK3ObgKFNd7Q7sF5MMO5VO8vb_Plubktz2mcbXSh7jDFGFNMNe7vFoJnxO0A2xQWIrrmawVUzpvCfR24AhsmjRw</recordid><startdate>19980501</startdate><enddate>19980501</enddate><creator>Ravn, P</creator><creator>Christensen, J.O</creator><creator>Baumann, M</creator><creator>Clemmesen, B</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980501</creationdate><title>Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment</title><author>Ravn, P ; Christensen, J.O ; Baumann, M ; Clemmesen, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-6f1efb8e22aff9e339340dac2478a536f22835384ab412e162c9d65e3c7cf7e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aged</topic><topic>Alkaline Phosphatase - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - urine</topic><topic>Bisophosphonate</topic><topic>Bone Density - drug effects</topic><topic>Bone Density - physiology</topic><topic>Bone Diseases, Metabolic - blood</topic><topic>Bone Diseases, Metabolic - drug therapy</topic><topic>Bone Diseases, Metabolic - urine</topic><topic>Bone Resorption - drug therapy</topic><topic>Bone turnover</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Collagen - blood</topic><topic>Collagen Type I</topic><topic>Diphosphonates - administration & dosage</topic><topic>Diphosphonates - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Femur - drug effects</topic><topic>Femur - physiology</topic><topic>Follow-Up Studies</topic><topic>Forearm</topic><topic>Humans</topic><topic>Ibandronate</topic><topic>Ibandronic Acid</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteocalcin - blood</topic><topic>Peptides - blood</topic><topic>Pharmacology. Drug treatments</topic><topic>Postmenopausal osteoporosis</topic><topic>Prediction</topic><topic>Spine - drug effects</topic><topic>Spine - physiology</topic><topic>Withdrawal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ravn, P</creatorcontrib><creatorcontrib>Christensen, J.O</creatorcontrib><creatorcontrib>Baumann, M</creatorcontrib><creatorcontrib>Clemmesen, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bone (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ravn, P</au><au>Christensen, J.O</au><au>Baumann, M</au><au>Clemmesen, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment</atitle><jtitle>Bone (New York, N.Y.)</jtitle><addtitle>Bone</addtitle><date>1998-05-01</date><risdate>1998</risdate><volume>22</volume><issue>5</issue><spage>559</spage><epage>564</epage><pages>559-564</pages><issn>8756-3282</issn><eissn>1873-2763</eissn><abstract>The study was a 1 year randomized, double-blind, placebo-controlled study of ibandronate treatment in postmenopausal, osteopenic women. Participants were followed for 1 year after withdrawal of treatment. All women were at least 10 years past menopause and had a baseline bone mineral density (BMD) at the distal forearm at least 1.5 standard deviations below the premenopausal mean peak value. A total of 141 women (78%) completed the first year, and 119 women (66%) the second year of the study. The dose-response data of the first year have been published previously (Ravn et al. Bone 19:527–533;1996). In this study, we analyzed the biochemical markers as predictors of response in bone mass during ibandronate treatment, and report withdrawal data from the last year of the study, when ibandronate was discontinued. The relative change in the biochemical markers was significantly correlated to the response in BMD. At 12 months, the
r values ranged from −0.29 to −0.47 (
p < 0.01) and were highest for CrossLaps (uCL) and osteocalcin (OC
N-MID). The quartiles of women with the most reduced concentrations of uCL and OC
N-MID during treatment showed a 360–430% higher response in BMD compared to quartiles with less reduced concentrations (
p < 0.01). During the withdrawal period, uCL and alkaline phosphatase (AP) returned to baseline values 12 months after discontinuation of treatment in all groups, whereas OC
N-MID and bone-specific AP were still reduced 10%–25% in the groups previously treated with the highest doses of ibandronate (1.0–5.0 mg) (
p < 0.01). In the withdrawal period, BMD decreased equally in all groups (analysis of variance; not significant); with a linear rate of 2%/year on average (
p < 0.05 to < 0.001) at the spine and femur. In conclusion, uCL and OC
N-MID can be used to predict the response in bone mass during ibandronate treatment. The bone loss that resumes after withdrawal of ibandronate treatment is of a magnitude similar to that of normal postmenopausal bone loss.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9600792</pmid><doi>10.1016/S8756-3282(98)00044-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8756-3282 |
| ispartof | Bone (New York, N.Y.), 1998-05, Vol.22 (5), p.559-564 |
| issn | 8756-3282 1873-2763 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79896514 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Alkaline Phosphatase - blood Biological and medical sciences Biomarkers - blood Biomarkers - urine Bisophosphonate Bone Density - drug effects Bone Density - physiology Bone Diseases, Metabolic - blood Bone Diseases, Metabolic - drug therapy Bone Diseases, Metabolic - urine Bone Resorption - drug therapy Bone turnover Bones, joints and connective tissue. Antiinflammatory agents Collagen - blood Collagen Type I Diphosphonates - administration & dosage Diphosphonates - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Female Femur - drug effects Femur - physiology Follow-Up Studies Forearm Humans Ibandronate Ibandronic Acid Medical sciences Middle Aged Osteocalcin - blood Peptides - blood Pharmacology. Drug treatments Postmenopausal osteoporosis Prediction Spine - drug effects Spine - physiology Withdrawal |
| title | Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A07%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20Biochemical%20Markers%20and%20Bone%20Mass%20After%20Withdrawal%20of%20Ibandronate%20Treatment:%20Prediction%20of%20Bone%20Mass%20Changes%20During%20Treatment&rft.jtitle=Bone%20(New%20York,%20N.Y.)&rft.au=Ravn,%20P&rft.date=1998-05-01&rft.volume=22&rft.issue=5&rft.spage=559&rft.epage=564&rft.pages=559-564&rft.issn=8756-3282&rft.eissn=1873-2763&rft_id=info:doi/10.1016/S8756-3282(98)00044-1&rft_dat=%3Cproquest_cross%3E79896514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79896514&rft_id=info:pmid/9600792&rft_els_id=S8756328298000441&rfr_iscdi=true |